Latest News

Fresh French fund for healthcare

© Grafikplusfoto/fotolia.com


09.09.2016 - iBionext’s healthcare VC fund iBionext Growth has announced a first closing of €46m. All in all, iBionext aims to take in around €100m to reinvest in biotech and medtech companies.

The fund has drawn interest from international investors, insurance companies and family offices, alongside the Biotech & Healthcare Acceleration Fund (FABS) operated by Bpifrance in the context of the Investments for the Future Program (PIA) managed by General Commissariat for Investment (CGI). Created in 2016 as an extension of the iBionext network established in 2012, iBionext Growth Fund is positioned as the missing link in the financing chain of innovative healthcare companies.

Alexia Perouse, CEO & Managing Partner of iBionext, commented: “We are delighted to have generated such momentum around our unique initiative and we thank our investors for the confidence they have placed in us. iBionext operates with a very entrepreneurial approach designed to meet the challenges that innovative healthcare companies can face, from creation to growth, with the goal of creating leaders in their field.”

The most notable creation of the iBionext network was GenSight Biologics, one of the few biotechs to successfully go public this year.

Dutch-Italian team improves retinal gene therapy

Retinal gene therapy with adeno-associated viral (AAV) vectors holds promises for treating inherited and noninherited diseases of the eye. Though...

Curetis lower respiratory tract panel ready for FDA clearance

With its 510(k) application to the US Food and Drug Administration (FDA), Curetis targets the US diagostics market for lower respiratory infections...

Evotec bags US$23.8m to fight tuberculosis

Evotec SE entered into a five-year partnership with the Bill & Melinda Gates Foundation to discover new treatment regimens that better address...

Ethics Council calls for moratorium of clinical germline manipulation

Last year, the birth of the first genetically modified babies in China shook the world. The German Ethics Council now presents a comprehensive...

Transgene’s licenced oncolytic virus fails in Phase III

The interim futility analysis focussed on the question if the oncolytic virus Pexa-Vec (pexastimogene devacirepvec) plus sorafenib (Nexavar, Bayer)...

Liquid biopsy identifies residual breast cancer

Their new mutation detection platform TARDIS showed a 100-fold improvement in sensitivity compared to established liquid biopsy technologies that...

Alizé Pharma 3 bags largest EU financing so far

The oversubscribed financing into the specialist for rare endocrine hormone dysbalances was led by Life Sciences Partners’ (LSP) LSP 6 fund with...